Treatment of arteriovenous malformations of the brain with combined embolization and stereotactic radiosurgery: results after 1 and 2 years

Seven patients with large arteriovenous malformations (AVMs) of the brain were selected for combined therapy with particulate embolization, followed by radiosurgery of the residual nidus. The goal of embolization was to reduce the patient nidus to a size that facilitated successful stereotactic radiosurgery. Angiograms obtained 1 and 2 years after radiosurgery were evaluated for changes in nidus size, flow rate, and feeding and draining vessels. One year after stereotactic radiosurgery, one AVM was angiographically undetectable. Three other AVMs demonstrated a volume reduction of greater than 50%, in addition to decreased shunt speed and altered angioarchitecture at 1-year follow-up. At 2-year follow-ups, two of seven AVMs were cured, and an additional two of seven had a greater than 98% reduction in nidus volume. Although one patient experienced a transient deficit from embolotherapy, none of our patients suffered a new neurologic deficit or a hemorrhage during the follow-up period. Our data support the efficacy of combined embolotherapy and radiosurgery for definitive therapy of selected large AVMs of the brain.     

Embolization of high-flow craniofacial vascular malformations with onyx

BACKGROUND AND PURPOSE: Various techniques and materials have been used for the endovascular treatment of craniofacial high-flow arteriovenous vascular malformations, because their rarity precludes standardization of their treatment. The aim of this retrospective review is to assess Onyx as the primary embolic agent in the treatment of these vascular malformations. MATERIALS AND METHODS: Six patients with arteriovenous fistulas and 3 with arteriovenous malformations (AVMs) of the head and neck region were treated with intra-arterial (IA)/direct percutaneous injections of Onyx. Adjunctive maneuvers used during embolization included external compression of the arterial feeders or venous outflow (6 patients), balloon assist (4 patients), and direct embolization of the draining vein remote to the fistula site (1 patient). n-butyl-2-cyanoacrylate (n-BCA) was used in addition to Onyx for rapid induction of thrombosis in a large venous pouch (1 patient) and for cost containment purposes (1 patient). Four patients were treated surgically after the embolization. RESULTS: There were no neurologic complications secondary to the embolization procedure. The arteriovenous shunt was eliminated in all of the fistulous lesions and 2 of the 3 AVMs. The embolization was incomplete in 1 patient with a large AVM who declined further endovascular or surgical procedures. Untoward events included 2 instances of catheter entrapment (of 9 IA injections), blackish skin discoloration necessitating surgical revision in 1 patient, and difficulty of balloon deflation/wire withdrawal during a balloon-assisted embolization. CONCLUSION: Onyx appears to be a safe and effective liquid embolic agent for use in the treatment of craniofacial high-flow vascular malformations with distinct advantages and disadvantages compared with n-BCA.     

Liquid Embolic Agents for Endovascular Embolization: Evaluation of an Established (Onyx) and a Novel (PHIL) Embolic Agent in an In Vitro AVM Model

BACKGROUND AND PURPOSE:Embolization plays a key role in the treatment of arteriovenous malformations. The aim of this study was to evaluate an established (Onyx) and a novel (precipitating hydrophobic injectable liquid [PHIL]) liquid embolic agent in an in vitro AVM model.MATERIALS AND METHODS:An AVM model was integrated into a circuit system. The artificial nidus (subdivided into 28 honeycomb-like sections) was embolized with Onyx 18 (group Onyx; n = 8) or PHIL 25 (group PHIL; n = 8) with different pause times between the injections (30 and 60 seconds, n = 4 per study group) by using a 1.3F microcatheter. Procedure times, number of injections, embolization success (defined as the number of filled sections of the artificial nidus), volume of embolic agent, and frequency and extent of reflux and draining vein embolization were assessed.RESULTS:Embolization success was comparable between Onyx and PHIL. Shorter pause times resulted in a significantly higher embolization success for PHIL (median embolization score, 28 versus 18; P = .011). Compared with Onyx, lower volumes of PHIL were required for the same extent of embolization (median volume per section of the artificial nidus, 15.5 versus 3.6 μL; P < .001).CONCLUSIONS:While the embolization success was comparable for Onyx and PHIL, pause time had a considerable effect on the embolization success in an in vitro AVM model. Compared with Onyx, lower volumes of PHIL were required for the same extent of embolization.

Arteriovenous malformations are complex vascular structures composed of feeding arteries, an intervening network of small pathologic blood vessels (the so-called nidus), and draining veins. The lack of an intervening capillary bed allows high-flow arteriovenous shunting of blood. While AVMs can occur throughout the entire body, cerebral AVMs are of particular relevance due to their ability to cause impairing neurologic symptoms and their considerable risk of hemorrhage.¹Alone or in combination with microneurosurgery and stereotactic radiation therapy, embolization plays an important role in the management of cerebral AVMs.² The aim of AVM embolization is complete filling of the nidus, while unwanted reflux into the feeding arteries should be minimized and premature embolization of the draining veins should be avoided.³A wide variety of embolic agents has been and is currently used for embolization of AVMs. At present, the liquid embolic agents (LEAs) ethylene-vinyl alcohol copolymer (EVOH) and n-butyl cyanoacrylate are used most frequently.⁴ Although the embolization results have improved since the introduction of EVOH-based LEAs with rates of complete obliteration ranging from 16% to 100%, the success rate of AVM embolization, especially for complex AVMs, is not yet satisfying.^2,3 Currently, new LEAs are being introduced to improve embolization features, such as embolization efficacy, intraprocedural handling, and control. Furthermore, their use should improve fluoroscopic visibility and reduce artifacts in postinterventional imaging.The aim of this study was to evaluate an established EVOH-based embolic agent and a novel copolymer-based embolic agent in an in vitro AVM model.     

Combined Treatment of Brain AVMs with Use of Onyx Embolization followed by Radiosurgery

BACKGROUND AND PURPOSE:The treatment of cerebral AVMs is complex, reliant on interventions such as embolization, surgery, and radiosurgery, or a combination of these modalities. To date, treatment with the embolic agent Onyx, followed by radiosurgery, has not been evaluated. The goal of this study was to evaluate the safety and efficacy of this combination in a homogeneous, monocentric series.MATERIALS AND METHODS:From April 2003 to June 2008, a total of 20 patients (11 women and 9 men; age range, 10–55 years) were treated for AVMs with Onyx embolization followed by radiosurgery. AVM sizes were <3 cm in 7 patients and ≥3 cm in 13 patients. Modalities and complications of the procedure were analyzed as well as the long-term clinical and anatomic outcomes (2–5 years after treatment).RESULTS:Of 17 patients evaluated by DSA after radiosurgery, 10 (58.8%) were observed to have complete occlusion of the AVM nidus. Complete occlusion was observed in 5 (71.4%) of 7 Spetzler-Martin grade I–II AVMs and in 5 (50.0%) of 10 Spetzler-Martin grade III–IV AVMs. Complete occlusion was observed in 4 (80.0%) of 5 AVMs of <3 cm and 6 (50.0%) of 12 AVMs of >3 cm. One of 20 patients had significant worsening of clinical status (mRS ≥2) at long-term follow-up.CONCLUSIONS:In this preliminary series, the safety and efficacy of combined treatment by Onyx embolization followed by radiosurgery are quite satisfactory, with a low rate of clinical complications (5.0%) and a 58.8% rate of complete obliteration of the AVM.

Cerebral AVMs are associated with significant morbidity and mortality related to intracerebral hemorrhage, seizures, and progressive neurologic decline.¹ The treatment of cerebral AVMs can be quite complicated, and indication for treatment in some clinical situations is controversial (eg, for asymptomatic AVMs). Moreover, several modalities of treatment are available (surgery, radiosurgery, and embolization), and these modalities can be used in combination for some AVMs.Several techniques are available for embolization, dependent on the embolization agent used and technique of microcatheterization. For many years, embolization with n-BCA has been standard clinical practice for the treatment of brain AVMs. In the last 10 years, n-BCA has been progressively replaced by Onyx (ev3, Irvine, California), a copolymer that precipitates when coming into contact with blood.^2–5 The progression of Onyx when injected into a brain AVM follows a lavalike flow pattern and is not associated with the risks of gluing the distal portion of the microcatheter as when using n-BCA. Onyx injections can be more prolonged and controlled compared with n-BCA, making it possible to occlude larger portions of the nidus during each injection.The combination of embolization and radiosurgery is often used in the treatment of brain AVMs; however, the effectiveness of this combination remains controversial. Some series have suggested that embolization before radiosurgery was associated with lower obliteration rates and worse outcomes.^6,7 Several mechanisms have been suggested to explain lower obliteration rates, including recanalization of the nidus after embolization, enhanced angiogenesis after embolization (as demonstrated in animal models), difficulty in delineation of the nidus after embolization, and beam attenuation by the liquid embolization material.In most studies dedicated to the combination therapy of embolization followed by radiosurgery for the treatment of brain AVMs, particles or glue were used as the embolization agent.^6,8,9 To our knowledge, no study to date has evaluated embolization with Onyx followed by radiosurgery. To very precisely evaluate the combined therapy of Onyx embolization and radiosurgery, we conducted a monocentric, retrospective study, with all patients having very homogeneous modalities of treatment with embolization and radiosurgery.     

Complete obliteration of intracranial arteriovenous malformation with endovascular cyanoacrylate embolization: initial success and rate of permanent cure

BACKGROUND AND PURPOSE: Endovascular treatment with cyanoacrylate embolization is an option when complete obliteration of the nidus of an intracranial arteriovenous malformation (AVM) is the goal. Our purpose was to evaluate the rates of initial success and permanent cure of such treatment in a Chinese population. METHODS: Twenty-seven consecutive patients with an intracranial AVM underwent endovascular embolization with cyanoacrylate between June 1995 and May 1997. Twenty-six patients had cerebral AVMs and one had a cerebellar AVM. Curative embolization was attempted in 10 patients in whom 1) the nidus was not larger than 3 cm, 2) the number of feeders did not exceed three, and 3) the nidus was accessible with the tip of the catheter. We used a flow-directed microcatheter and a 20-25% mixture of cyanoacrylate in contrast medium. Long-term outcomes were observed angiographically and clinically. RESULTS: Complete embolization was achieved in six patients. No procedure-related complications occurred during attempted curative embolization. Follow-up angiography performed at 17-32 months showed complete obliteration of the AVM nidus in the six patients after initial embolization. These patients remained asymptomatic 5-7 years after treatment. The rate of permanent cure of the initially complete embolization was 100% (six of six). The success rate of endovascular cure for patients treated with curative intent was 60% (six of 10). The overall cure rate was 22% (six of 27). CONCLUSION: The overall initial cure rate of intracranial AVM with cyanoacrylate embolization was 22%. Initial angiographic evidence of complete embolization indicated permanent cure in these patients.     

Angiographic and clinical characteristics of patients with cerebral arteriovenous malformations associated with hereditary hemorrhagic telangiectasia

BACKGROUND AND PURPOSE: Cerebral arteriovenous malformations (AVMs) are occasionally associated with hereditary hemorrhagic telangiectasia (HHT), which is characterized by the presence of multiple mucocutaneous telangiectasia, epistaxis, and familial inheritance. We analyzed the angiographic and clinical characteristics of patients with cerebral AVMs related to HHT. METHODS: Among 638 patients with cerebral AVMs, we identified 14 patients with HHT. The AVMs were classified as those with nidi of 1 cm or less (micro AVMs), those with nidi between 1 and 3 cm (small AVMs), and those of the fistulous type (arteriovenous fistulas [AVFs]). RESULTS: A total of 28 AVMs were found; seven of 14 patients had multiple AVMs. The 28 AVMs were categorized as 12 micro AVMs, eight small AVMs, and eight AVFs. All except one micro AVM were asymptomatic, whereas all small AVMs were symptomatic. Three of eight AVFs were asymptomatic. All 28 AVMs were located on the cortex. All micro AVMs and AVFs had single feeders and single draining veins, whereas the small AVMs had multiple feeders in all lesions and single draining veins in six of eight lesions. CONCLUSION: Multiple, cortical, micro AVMs or AVFs harboring single feeding arteries and single draining veins should raise clinical suspicion of HHT-related AVMs.     

Curative embolization of cerebral arteriovenous malformations (AVMs) with Onyx in 101 patients

INTRODUCTION: Onyx has emerged in the recent years as a new embolic material. We present our experience with Onyx in the curative embolization of brain cerebral arteriovenous malformations (AVMs). METHODS: We retrospectively reviewed the files of all patients that we had treated with Onyx embolic material for a brain AVM during the last 4 years. We identified 101 patients who underwent a total of 219 sessions of embolization. RESULTS: The treatment has been concluded in 52 patients; in this group, total occlusion was obtained in 28 (53.9%) patients and near-total occlusion was obtained in 18 (34.6%). The respective figures based on the 101 patients of the study cohort are 28/101 (27.7%) and 18/101 (17.8%). More embolization sessions are to be carried out on the remaining 49 patients. There were three deaths, and eight patients had permanent neurological deficits with a resulting morbidity of 8% and mortality of 3%. CONCLUSION: High rates of total or near-total occlusion of brain AVMs can be achieved with multiple sessions of Onyx embolization with acceptable morbidity and mortality.     

MR imaging in the management of supratentorial intracranial AVMs

The MR images, CT scans, and angiograms of 15 consecutive patients with intracranial, supratentorial arteriovenous malformations (AVMs) were studied retrospectively. The three imaging techniques were evaluated separately to assess their utility in defining the size, characteristics, and location of the AVM nidus, its arterial supply, and venous drainage. The studies were also evaluated for their ability to show associated parenchymal abnormalities, the presence of mass effect, and changes occurring after embolization. MR was superior to both CT and angiography in showing the exact anatomic relationships of the nidus, feeding arteries, and draining veins, as well as in demonstrating the extent of AVM nidus obliteration after embolization. MR was more sensitive than CT in revealing associated parenchymal abnormalities and subacute hemorrhage. Because of flow-related artifacts and low sensitivity in distinguishing calcification from rapid flow and/or hemosiderin, MR seemed to have a low sensitivity for detecting old hemorrhage within an AVM nidus. Angiography is still needed in the planning of either surgical or endovascular treatment of AVMs.     

Angiographic follow-up of large cerebral AVMs incompletely embolized with isobutyl-2-cyanoacrylate

This study evaluated the long-term angiographic results in large cerebral arteriovenous malformations (AVMs) partially embolized with isobutyl-2-cyanoacrylate. Preembolization, immediate postembolization, and long-term follow-up angiograms were performed in 30 large, partially embolized brain AVMs. Particular attention was paid to the relative size of the residual AVM nidus and the embolized arterial feeders, to recruitment of new feeders, to the size of residual draining veins, and to the speed of arteriovenous shunt. Nine cases with less than 50% AVM nidus obliteration showed no significant morphologic changes. In 18 cases with 50-75% obliteration of the AVM nidus, 11 (61.1%) showed no significant changes, six (33.3%) showed enlargement of the AVM nidus, and one (5.5%) evolved to complete angiographic obliteration. In three cases with 75-99% AVM nidus obliteration, one remained unchanged, one showed an increase in the size of the AVM nidus, and one evolved to complete obliteration. Evaluation by plain film, CT, and cerebral angiography of the isobutyl-2-cyanoacrylate deposits showed that when the polymer was positioned predominantly in arterial feeders there was invariably reconstitution of the AVM nidus through leptomeningeal, deep medullary, and/or dural collaterals. This phenomenon did not occur when the isobutyl-2-cyanoacrylate was deposited mainly in the AVM nidus.     

Contrast-enhanced MRA for investigation of cerebral arteriovenous malformations

We evaluated contrast-enhanced MRA (enhanced 3-D fast gradient-echo [efgre3d] with spectral inversion recovery) for identification of 15 intracranial arteriovenous malformations (AVMs) in 14 patients. Demonstration of the feeding arteries was classified as good for 16 examinations on maximum-intensity projections and multiprojection volume reconstruction images. The nidus was seen well in all patients. Definition of the draining veins was good or fair except for one poor result. Therapeutic effects were clearly demonstrated in three follow-up series. Contrast-enhanced MRA using efgre3d is useful for delineation of AVMs and for follow-up after treatment.     

Assessment of 3D-TOF-MRA at 3.0 Tesla in the characterization of the angioarchitecture of cerebral arteriovenous malformations: a preliminary study

Background: The characterization of brain arteriovenous malformation (AVM) angioarchitecture remains rewarding in planning and predicting therapy. The increased signal-to-noise ratio at higher field strength has been found advantageous in vascular brain pathologies.

Purpose: To evaluate whether 3.0T time-of-flight (TOF) magnetic resonance angiography (MRA) is superior to 1.5T TOF-MRA for the characterization of cerebral AVMs.

Material and Methods: Fifteen patients with AVM underwent TOF-MRA at 3.0T and 1.5T and catheter angiography (DSA), which was used as the gold standard. Blinded readers scored image quality on a four-point scale, nidus size, and number of feeding arteries and draining veins.

Results: Image quality of TOF-MRA at 3.0T was superior to 1.5T but still inferior to DSA. Evaluation of nidus size was equally good at 3.0T and 1.5T for all AVMs. In small AVMs, however, there was a tendency of size overestimation at 3.0T. MRA at 3.0T had increased detection rates for feeding arteries (+21%) and superficial (+13%) and deep draining veins (+33%) over 1.5T MRA.

Conclusion: 3.0T TOF-MRA offers superior characterization of AVM angioarchitecture compared with 1.5T TOF-MRA. The image quality of MRA at both 3.0 and 1.5T is still far from equal to DSA, which remains the gold standard for characterization of AVM.     

血管内介入治疗硬脑膜动静脉瘘的新进展

硬脑膜动静脉瘘是较常见的颅内血管畸形,目前尚无理想治疗方案,且易并发脑出血。数字减影血管造影(DSA)技术可清楚显示瘘口发生部位、供血动脉及引流静脉,是诊断硬脑膜动静脉瘘的金标准。本研究着重介绍新型材料Onyx在血管内栓塞治疗中的应用、疗效与注意事项,主要探讨血管内介入治疗硬脑膜动静脉瘘的研究新进展。     

Three-dimensional dynamic magnetic resonance angiography for the evaluation of radiosurgically treated cerebral arteriovenous malformations

We assessed the value of three-dimensional (3D) dynamic magnetic resonance angiography (MRA) for the follow-up of patients with radiosurgically treated cerebral arteriovenous malformations (AVMs). Fifty-four patients with cerebral AVMs treated by radiosurgery (RS) were monitored using conventional catheter angiography (CCA) and 3D dynamic MRA with sensitivity encoding based on the parallel imaging. Cerebral AVM was qualitatively classified by two radiologists into one of five categories in terms of residual nidus size and persistence of early draining vein (I, >6 cm; II, 3–6 cm; III, <3 cm; IV, isolated early draining vein; V, complete obliteration). 3D MRA findings showed a good agreement with CCA in 40 cases (κ=0.62). Of 23 nidus detected on CCA, 3D dynamic MRA showed 14 residual nidus. Of 28 occluded nidus on 3D dynamic MRA, 22 nidus were occluded on CCA. The sensitivity and specificity of 3D dynamic MRA for the detection of residual AVM were 81% and 100%. 3D dynamic MRA after RS may therefore be useful in association with MRI and can be repeated as long as opacification of the nidus or early venous drainage persists, one CCA remaining indispensable to affirm the complete occlusion at the end of follow-up.     

Can Induction of Systemic Hypotension Help Prevent Nidus Rupture Complicating Arteriovenous Malformation Embolization?: Analysis of Underlying Mechanisms Achieved Using a Theoretical Model

BACKGROUND AND PURPOSE: Nidus rupture is a serious complication of intracranial arteriovenous malformation (AVM) embolotherapy, but its pathogenetic mechanisms are not well described. An AVM model based on electrical network analysis was used to investigate theoretically the potential role of hemodynamic perturbations for elevating the risk of nidus vessel rupture (Rrupt) after simulated AVM embolotherapy, and to assess the potential benefit of systemic hypotension for preventing rupture. METHODS: Five separate hypothetical mechanisms for nidus hemorrhage were studied: 1) intranidal rerouting of blood pressure; 2) extranidal rerouting of blood pressure; 3) occlusion of draining veins with glue; 4) delayed thrombosis of draining veins; and 5) excessively high injection pressures proximal to the nidus. Simulated occlusion of vessels or elevated injection pressures were implemented into the AVM model, and electrical circuit analysis revealed the consequent changes in intranidal flow, pressure, and Rrupt for the nidus vessels. An expression for Rrupt was derived based on the functional distribution of the critical radii of component vessels. If AVM rupture was observed (Rrupt > or = 100%) at systemic normotension (mean pressure [P] = 74 mm Hg), the theoretical embolization was repeated under systemic hypotension (minor P = 70 mm Hg, moderate P = 50 mm Hg, or profound P = 25 mm Hg) to assess the potential benefit of this maneuver in reducing hemorrhage rates. RESULTS: All five pathogenetic mechanisms under investigation were able to produce rupture of AVMs during or after embolotherapy. These different mechanisms had in common the capability of generating surges in intranidal hemodynamic parameters resulting in nidus vessel rupture. The theoretical induction of systemic hypotension during and after treatment was shown to be of significant benefit in attenuating these surges and reducing Rrupt to safer levels below 100%. CONCLUSION: The induction of systemic hypotension during and after AVM embolization would appear theoretically to be of potential use in preventing iatrogenic nidus hemorrhage. The described AVM model should serve as a useful research tool for further theoretical investigations of AVM embolotherapy and its hemodynamic sequelae.     

MR动态减影血管造影在脑动静脉畸形治疗前后中的评价

目的评价MR动态减影血管造影（MR-DSA）在脑动静脉畸形（AVM）栓塞治疗前后的价值和限度。方法22例AVM患者，在栓塞前后均行MR—DSA、三维增强MR血管造影（3D—CEMRA）、MR质子加权成像（PWI）和DSA检查，同时由2名有经验的医生独立进行双盲对照研究。结果MR-DSA和DSA在22例AVM栓塞前后的瘤巢大小及分类上结果一致，MR—DSA能够显示AVM栓塞后的血液动力学改变，瘤巢及引流静脉显影推迟17例，瘤巢变小13例（其中完全消失4例），与DSA符合率为100％。与DSA相比，MR-DSA没有显示瘤巢内动脉瘤和栓塞后引流静脉及供血动脉直径变小各1例，而3D-CEMRA对此显示清晰。栓塞后的PWI与栓塞前相比，22例均可见不同程度的高信号。结论MR—DSA是1种快速、有效、无创的血管造影检查方法，能提供AVM栓塞前后的血流动力学信息，MR—DSA、3D-CEMRA和PWI应在AVM的随访中相互结合，综合运用。     

Brain AVM embolization with Onyx

BACKGROUND AND PURPOSE: To report the initial experience by using a new liquid embolic agent (Onyx) for embolization of brain arteriovenous malformations (AVMs). METHODS: Between May 2000 and December 2005, 44 patients with brain AVMs were embolized with Onyx. There were 18 women and 26 men with a mean age of 42.4 years (median 44, range 14-71 years). Clinical presentation included seizures in 26 patients (59%), hemorrhage from the AVM in 13 patients (30%), subarachnoid hemorrhage from a concomitant aneurysm in 3 patients (7%), visual disturbances in 1 patient (2.3%), and in 1 patient (2.3%) the AVM was an incidental finding. Mean estimated size of the AVM was 3.9 cm (median 4, range 2-7 cm). RESULTS: In 44 patients, 52 embolization procedures were performed with 138 feeding pedicles embolized, ranging from 1 to 7 per patient. Average estimated size reduction was 75% (median 80%, range 40%-100%). Total obliteration was achieved in 7 AVMs (16%), and partial embolization was followed by surgery in 10 patients and by radiosurgery in 20 patients. Complications occurred in 6 patients, leading to death in 1 patient (mortality 2.3%) and to permanent disability in 2 patients (morbidity 4.6%). CONCLUSION: Onyx is feasible and safe in the embolization of brain AVMs. Complete obliteration can be achieved in small AVMs. Large AVMs can be adequately reduced in size for additional surgical or radiosurgical treatment.     

Subclassification and Treatment Results of Ethanol Embolotherapy of Type II Arteriovenous Malformations of the Extremity and Body

PurposeTo evaluate the safety and efficacy of ethanol and coil embolization of type II arteriovenous malformation (AVM) according to a new subtype classification.Materials and MethodsEighty-four type II AVMs in the body or extremity of 79 patients who underwent AVM treatment from 1996 to 2017 were retrospectively subclassified according to the angiographic morphology of the draining vein as type IIa (arterioles shunt to focal segment of single draining vein), type IIb (arterioles shunt to venous sac with multiple draining veins), and type IIc (arterioles shunt along long segment of draining vein). Coil and ethanol embolization of the focal or long segment of the draining vein or the venous sac was performed with direct puncture or transvenous approach according to subtype. Treatment outcomes, number of treatment sessions, and complications were analyzed.ResultsAVM cure (ie, complete embolization) rates were 95%, 76%, and 65% in types IIa, IIb, and IIc AVMs, respectively. The cure rate of type IIa AVMs was significantly better than that of type IIc AVMs (P = .015). Median numbers of treatment sessions were 1 in types IIa and IIb AVMs and 2.5 in type IIc AVMs, with a significant difference between type IIc and the other 2 types (P < .05). Minor complications occurred in 20% of patents and major complications occurred in 7%.ConclusionsThe cure rate of type IIa AVMs was significantly better than that of type IIc AVMs, which also required significantly more treatment sessions than the other 2 types.     

MR-DSA在评价脑动静脉畸形栓塞前后的价值和限度

目的 评价动态MR血管造影(MR—DSA)在观察脑动静脉畸形栓塞前后的价值和限度。资料与方法 22例脑动静脉畸形患者，在栓塞前后均行MR—DSA、三维增强MR血管造影(3D—CEMRA)、质子加权成像(proton imaging)和数字减影血管造影(DSA)检查，同时由2位有经验的医师独立进行双盲对照研究。结果 MR—DSA和DSA在22例脑动静脉畸形栓塞前后的瘤巢大小及分类上结果一致(100％)，MR—DSA能够显示脑动静脉畸形栓塞后的血流动力学改变，瘤巢及引流静脉延迟显影17例，瘤巢变小13例(其中完全消失4例)，与DSA的符合率为100％。与DSA相比，分别有瘤巢内动脉瘤和栓塞后引流静脉及供血动脉直径变小各1例，MR—四A没有显示，而3D—CEMRA显示清晰。栓塞后的质子加权图像与栓塞前相比，22例均可见不同程度的高信号。结论 MR—DSA是一种快速、有效且无创的血管造影检查方法，能提供脑动静脉畸形栓塞前后的血流动力学信息，MR，DSA、3D—CEMRA和质子加权成像应在脑动静脉畸形的随访中相互结合，综合运用。     

Cerebral MR venography

This paper illustrates the technique and clinical use of cerebral MR venography (MRV). Dural sinus thrombosis is detected by both two-dimensional time-of-flight (TOF) and three-dimensional phase-contrast (PC) techniques. Venous angiomas are demonstrated by the three-dimensional PC method. The arterial feeders, nidus and draining veins of cerebral arteriovenous malformation (AVM) can be visualized on contrast-enhanced TOF three-dimensional MR angiogram. The high-flow draining veins of cerebral and dural AVMs, vein of Galen malformation and carotid cavernous fistula are better seen on contrast-enhanced three-dimensional gradient-echo MRV.     

External carotid artery embolization of dural arteriovenous malformations involving the cavernous sinus. Outcome and role of venous thrombosis

Nine patients with dural arteriovenous malformations (AVMs) in the region of the cavernous sinus were treated by means of external carotid artery (ECA) embolization using polyvinyl alcohol. All AVMs received vascular supply from both the ECA and the internal carotid artery. Seven cases were clinically cured after embolization, while 2 cases with cortical venous drainage and high flow through the shunt were not completely cured. Venous thrombosis was observed in 5 cases before and in 9 after embolization. In 6 cases the drainage pattern changed owing to venous thrombosis. Complete thrombosis of the cavernous sinus was found on a follow-up angiography in 2 cases. Formation of venous thrombosis and occlusion of feeding arteries are crucial factors for success of ECA embolization. Dural AVMs with cortical venous drainage and high flow cannot be relieved by ECA embolization alone owing to difficulty in obtaining thrombosis of the veins.